Northland Securities analyst Jason Wittes maintained a Buy rating on Zimmer Biomet Holdings (NYSE:ZBH) on Tuesday, setting a price target of $200, which is approximately 22.69% above the present share price of $163.01.
Wittes expects Zimmer Biomet Holdings to post earnings per share (EPS) of $0.95 for the third quarter of 2021.
The current consensus among 16 TipRanks analysts is for a Strong Buy rating of shares in Zimmer Biomet Holdings, with an average price target of $194.25.
The analysts price targets range from a high of $210 to a low of $160.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.85 billion and a net profit of $300.8 million. The company's market cap is $33.98 billion.
According to TipRanks.com, Northland Securities analyst Jason Wittes is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.2% and a 58.29% success rate.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.